Patients with high-risk localized prostate cancer (HR LPC) are at significant risk of developing systemic or local recurrence as well as symptoms and/or death from the disease.1 While there is a range of treatment options available, including radical prostatectomy (RP), radiation therapy with or wit

Prostate cancer remains a leading cause of cancer-related deaths in men.^1,2 Despite early detection and treatment, the mortality burden of early prostate cancer by 75 years of age remains high.^1,2 A recent cohort study has estimated that among men at higher genetic risk, one-third of early prostate cancer deaths were preventable by adherence to a healthy lifestyle, suggesting that prostate cancer prevention strategies should target men with higher genetic risk.¹

The advent of novel strategies has shifted the treatment paradigm of metastatic hormone-sensitive prostate cancer (mHSPC) from androgen deprivation therapy (ADT) monotherapy to combination therapies.¹ Upfront addition of chemotherapy or androgen receptor (AR) inhibitors to ADT has demonstrated an improved overall survival (OS) and become a new standard of care (SoC) in this therapeutic area.² The early treatment intensification is particularly important and beneficial to mHSPC patients with high volume of disease.^3,4 In an interview with Omnihealth Practice,  Dr. Lee, Siu-Hong discussed the unmet needs in mHSPC, emphasizing the importance of using combination therapy for the high-volume patients. He also stressed the significance of monitoring prostate-specific antigen (PSA) response and shared a clinical case of a 70-year-old male diagnosed with de novo mHSPC with high volume of disease who was managed with upfront ADT + enzalutamide, then achieving a rapid reduction in the serum PSA levels. 

At the Uro-Oncology Asia 2021 Conference organized by the Hong Kong Society of Uro-Oncology, Dr. Joaquin Mateo, medical oncologist and attending physician at the Vall d’Hebron University Hospital, Barcelona, and principal investigator at the Vall d’Hebron Institute of Oncology, discussed the importa

Prostate cancer was the third most common cancer among males in Hong Kong in 2018, accounting for 12.9% of total cancer cases and 5.5% of total cancer deaths.1 For decades, the anatomical extent or stage of cancer has been classified using the tumor-node-metastasis (TNM) system, but not for localize

Based on the Prostate Cancer Working Group (PCWG) 3 consensus, prostate cancer patients are considered castration-resistant when a minimum rise of 2ng/mL in prostate-specific antigen (PSA) level is observed after androgen depletion therapy (ADT).1 Previously, castration-resistant prostate cancer pat

Due to the co-existing prostate-specific antigen (PSA) raising and lowering factors, the commonly used PSA screening test often lacks sufficient sensitivity or specificity to accurately predict prostate cancer (PCa).¹ Spermine, a novel non-prostate massage urine biomarker, was recently shown to be

Multiple systemic options have been considered for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Despite significant advances in these therapies, the median overall survival (OS) in the first-line setting is only 3 years.^1,2

Prostate cancer (PCa) has the highest reported incidence rate among common male cancers in Hong Kong during the past two decades.¹ It is the fourth leading cause of cancer-related deaths among males in Hong Kong.

Prostate cancer (PCa) is the most common cancer affecting men in Europe and the United States.¹ While non-metastatic PCa has a 5-year survival rate of 98.9%, the corresponding rate for metastatic PCa is less than 30%.²